Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle M Mello

Showing results (121-130 of 261) with videos related to

Pageof 27
Sort By:
The New England Journal of Medicine|February 6, 2004
The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costsMichelle M Mello, David M Studdert, Troyen A Brennan
The New England Journal of Medicine|January 16, 2004
Medical malpracticeDavid M Studdert, Michelle M Mello, Troyen A Brennan
The New England Journal of Medicine|June 27, 2020
Ensuring Uptake of Vaccines against SARS-CoV-2Michelle M Mello, Ross D Silverman, Saad B Omer
The New England Journal of Medicine|August 24, 2012
Ethical considerations in studying drug safety--the Institute of Medicine reportMichelle M Mello, Steven N Goodman, Ruth R Faden
Health Economics|May 15, 2002
Do Medicare HMOs still reduce health services use after controlling for selection bias?Michelle M Mello, Sally C Stearns, Edward C Norton
Plos Medicine|April 13, 2011
Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaintsAaron S Kesselheim, Michelle M Mello, David M Studdert
Health Affairs (Project Hope)|April 4, 2003
The Leapfrog standards: ready to jump from marketplace to courtroom?Michelle M Mello, David M Studdert, Troyen A Brennan
JAMA|February 18, 2003
Medical monitoring for pharmaceutical injuries: tort law for the public's health?David M Studdert, Michelle M Mello, Troyen A Brennan
Health Affairs (Project Hope)|December 3, 2003
The McLawsuit: the fast-food industry and legal accountability for obesityMichelle M Mello, Eric B Rimm, David M Studdert
Accountability in Research|April 26, 2006
Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsorsMichelle M Mello, Brian R Clarridge, David M Studdert
Pageof 27

Showing results (121-130 of 261) with videos related to

Sort By:
Pageof 27
The New England Journal of Medicine|February 6, 2004
The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costsMichelle M Mello, David M Studdert, Troyen A Brennan
The New England Journal of Medicine|January 16, 2004
Medical malpracticeDavid M Studdert, Michelle M Mello, Troyen A Brennan
The New England Journal of Medicine|June 27, 2020
Ensuring Uptake of Vaccines against SARS-CoV-2Michelle M Mello, Ross D Silverman, Saad B Omer
The New England Journal of Medicine|August 24, 2012
Ethical considerations in studying drug safety--the Institute of Medicine reportMichelle M Mello, Steven N Goodman, Ruth R Faden
Health Economics|May 15, 2002
Do Medicare HMOs still reduce health services use after controlling for selection bias?Michelle M Mello, Sally C Stearns, Edward C Norton
Plos Medicine|April 13, 2011
Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaintsAaron S Kesselheim, Michelle M Mello, David M Studdert
Health Affairs (Project Hope)|April 4, 2003
The Leapfrog standards: ready to jump from marketplace to courtroom?Michelle M Mello, David M Studdert, Troyen A Brennan
JAMA|February 18, 2003
Medical monitoring for pharmaceutical injuries: tort law for the public's health?David M Studdert, Michelle M Mello, Troyen A Brennan
Health Affairs (Project Hope)|December 3, 2003
The McLawsuit: the fast-food industry and legal accountability for obesityMichelle M Mello, Eric B Rimm, David M Studdert
Accountability in Research|April 26, 2006
Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsorsMichelle M Mello, Brian R Clarridge, David M Studdert
Pageof 27